)
)
Rain Therapeutics Inc Investor Relations Material
Latest events
Q2 2023
Rain Therapeutics Inc
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Rain Therapeutics Inc
Access all reports
Rain Oncology Inc. (formerly Rain Therapeutics Inc.) is a biotechnology company focused on developing precision oncology therapies. It targets oncogenic drivers to select patients based on the genetic profile of their tumors. The company's lead product candidate, milademetan, is an oral small-molecule inhibitor designed to block the MDM2-p53 interaction, a key pathway in many cancers. Rain Oncology is also advancing preclinical programs, including a RAD52 inhibitor aimed at exploiting synthetic lethality in certain cancer types with homologous recombination deficiencies. The company is headquartered in Newark, California, and its shares trade on the NASDAQ.
Latest articles
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
)
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
)
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
RAIN
Country
🇺🇸 United States